Levosimendan
Levosimendan is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
108 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | — | 1 | 5 | 4 | 1 | 11 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | — | 1 | 1 | 2 |
| Coronary disease | D003327 | — | — | — | 1 | — | 1 | — | 2 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | — | 1 | — | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | — | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | — | 1 | 2 | — | — | 3 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 1 | 2 | — | — | 3 |
| Sclerosis | D012598 | — | — | — | 1 | 1 | — | — | 2 |
| Low cardiac output | D002303 | — | — | — | 1 | 1 | — | — | 1 |
| Muscle weakness | D018908 | HP_0001324 | — | — | 1 | 1 | — | — | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 1 | 1 | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 2 | — | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | — | 1 |
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | 1 | — | — | — | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | — | — | — | 1 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Left ventricular dysfunction | D018487 | — | — | — | — | — | — | 1 | 1 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 1 | 1 |
| Ventricular dysfunction | D018754 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Levosimendan |
| INN | levosimendan |
| Description | Levosimendan is a hydrazone, a pyridazinone and a nitrile. It has a role as a vasodilator agent, an EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor, a cardiotonic drug and an anti-arrhythmia drug. |
| Classification | Small molecule |
| Drug class | positive inotropic agents (pimobendan type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 141505-33-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2051955 |
| ChEBI ID | 50567 |
| PubChem CID | 3033825 |
| DrugBank | DB00922 |
| UNII ID | C6T4514L4E (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,502 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
173 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use